CA
INMB icon

Clearstead Advisors’s INmune Bio INMB Stock Holding History

Clearstead Advisors’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-590
Closed -$4.61K – 2811
2025
Q1 		$4.61K Buy
590
+100
+20% +$794 ﹤0.01% 1768
2024
Q4 		$2.29K Hold
490
– – ﹤0.01% 1830
2024
Q3 		$2.64K Hold
490
– – ﹤0.01% 1812
2024
Q2 		$4.32K Hold
490
– – ﹤0.01% 1706
2024
Q1 		$4.86K Buy
490
+70
+17% +$846 ﹤0.01% 1179
2023
Q4 		$4.73K Sell
420
-420
-50% -$3.52K ﹤0.01% 1169
2023
Q3 		$5.69K Buy
840
+420
+100% +$3.48K ﹤0.01% 1215
2023
Q2 		$3.81K Hold
420
– – ﹤0.01% 1076
2023
Q1 		$2.71K Buy
+420
New +$3.38K ﹤0.01% 1091

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Clearstead Advisors's INMB Position: Q2 2025 in Review

Clearstead Advisors sold out of INmune Bio (INMB) in Q2 2025, closing a stake of 590 shares — an estimated $4.61K sold.

Clearstead Advisors first reported a position in INMB in Q1 2023 and held it in 9 quarters. The position peaked at $5.69K in Q3 2023. 79 funds tracked by Wall St. Rank hold INMB as of Q2 2025.

  • Clearstead Advisors reported no remaining INmune Bio position as of Q2 2025 after selling out during the quarter.
  • Clearstead Advisors sold 590 INmune Bio shares in Q2 2025, an estimated $4.61K.
  • Clearstead Advisors first reported a position in INmune Bio in Q1 2023 and held it in 9 quarters.
  • Clearstead Advisors's INmune Bio position peaked at $5.69K in Q3 2023.
  • 79 funds tracked by Wall St. Rank held INmune Bio as of Q2 2025.

Based on Clearstead Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.